Conference Coverage

Low-dose aspirin reduces liver fat, inflammation markers


 

AT THE LIVER MEETING 2023

Significant weight gain in placebo group

Mary E. McCarthy Rinella, MD, FAASLD, professor of medicine at the University of Chicago, commented that the 4% increase in liver fat in the control arm “is kind of a lot for a placebo, and I’m wondering how much that accounts for the [difference] that you saw.” Dr. Rinella served as a comoderator of the session.

Dr. Wilechansky said that there were a few outliers in the placebo group who experienced significant weight gain during the study, including one patient who gained 15 kg over 6 months.

A post hoc analysis suggested that most of the increase in hepatic fat among patients who took placebo could have been among that handful of patients, he added. When those patients were removed in an adjusted analysis, the difference between the aspirin and placebo groups was smaller but remained significant.

The trial was sponsored by Massachusetts General Hospital. Dr. Wilechansky, Dr. Rinella, and Dr. Hartman had no relevant disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Cause of common gastrointestinal symptoms in diabetes?
MDedge Endocrinology
Medicare announces 10 drugs targeted for price cuts in 2026
MDedge Endocrinology
MASLD: Promising treatments for a newly renamed disease
MDedge Endocrinology
FDA gives semaglutide two drug safety–related label changes
MDedge Endocrinology
The new word in liver disease: The story behind NAFLD’s rebranding as MASLD
MDedge Endocrinology
Bariatric surgery, including sleeve gastrectomy, linked to fracture risk
MDedge Endocrinology
SGLT2 inhibitors in type 2 diabetes linked to lower risk of developing GI cancers
MDedge Endocrinology
Does diabetes affect colorectal cancer outcomes?
MDedge Endocrinology
Weight-loss drugs improve liver measures, too
MDedge Endocrinology
People with diabetes have a higher risk of colon cancer: Study
MDedge Endocrinology